May 2, 2021 Journal article Open Access

Ayoubi, Riham; McPherson, Peter S.; Laflamme, Carl

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.4733123</identifier>
  <creators>
    <creator>
      <creatorName>Ayoubi, Riham</creatorName>
      <givenName>Riham</givenName>
      <familyName>Ayoubi</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-6633-655X</nameIdentifier>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
    <creator>
      <creatorName>McPherson, Peter S.</creatorName>
      <givenName>Peter S.</givenName>
      <familyName>McPherson</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-7806-5662</nameIdentifier>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
    <creator>
      <creatorName>Laflamme, Carl</creatorName>
      <givenName>Carl</givenName>
      <familyName>Laflamme</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-5906-025X</nameIdentifier>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Antibody Characterization Report for Solute carrier family 2, facilitated glucose transporter member 6 SLC2A6 (GLUT-6)</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2021</publicationYear>
  <subjects>
    <subject>Solute carrier family 2, facilitated glucose transporter member 6</subject>
    <subject>Glucose transporter type 6</subject>
    <subject>GLUT-6</subject>
    <subject>SLC2A6</subject>
    <subject>Q9UGQ3</subject>
    <subject>antibody characterization</subject>
    <subject>antibody validation</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2021-05-02</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/4733123</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.4733122</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/openlabnotebooks</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/sgc-opennotebook</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/ycharos</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Head to head comparison of available commercial antibodies against Solute carrier family 2, facilitated glucose transporter member 6&amp;nbsp;&lt;strong&gt;SLC2A6 &lt;/strong&gt;(GLUT-6) by immunoblot (Western blot).&amp;nbsp;Work performed in collaboration with the RESOLUTE consortium (&lt;a href="http://re-solute.eu/"&gt;re-solute.eu&lt;/a&gt;). RESOLUTE received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (RESOLUTE grant No 777372).&lt;/p&gt;</description>
  </descriptions>
</resource>